In comparison to ICIs + CT, this regimen also presented a tendency of OS superiority, although the difference did not reach statistical significance, except for ipilimumab + CT with HR of 0.65.
← all excerpts
Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.
1
—
—